Cambridge Cognition Holdings PLC Director/PDMR Share Purchases
31 January 2024 - 3:20AM
RNS Regulatory News
RNS Number : 4188B
Cambridge Cognition Holdings PLC
30 January 2024
30 January 2024
Cambridge Cognition Holdings
Plc
("Cambridge Cognition", the "Company" or the
"Group")
Director/PDMR Share
Purchases
Cambridge Cognition Holdings Plc
(AIM: COG), which develops and markets digital solutions to assess
brain health, was informed on 30 January
2024 that Nick Rodgers, Non-Executive Director of the Company,
purchased 20,000 ordinary shares of 0.01 pence each ("Ordinary
Shares") in the Company at a price of 52.449 pence per
share.
Following this transaction, Nick
Rodgers holds an interest in 20,000 Ordinary Shares, representing
approximately 0.06% of the Company's issued share
capital.
Further information on the purchases
is contained in the disclosure tables below.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM:
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Nick Rodgers
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Non-Executive Director
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Cambridge Cognition Holdings
Plc
|
b)
|
LEI
|
213800SZKDIN122EPA96
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares of 0.01p
each
GB00B8DV9647
|
b)
|
Nature of the transaction
|
Purchase of Shares
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
52.449 pence
|
20,000
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
e)
|
Date of the transaction
|
30 January 2024
|
f)
|
Place of the transaction
|
London Stock Exchange
|
For
further information, please contact:
Cambridge Cognition Holdings Plc
Matthew Stork, Chief Executive
Officer
Stephen Symonds, Chief Financial
Officer
|
Tel: 012 2381
0700
press@camcog.com
|
Panmure Gordon (UK) Limited (NOMAD and Joint
Broker)
Freddy Crossley / Emma
Earl
Rupert Dearden
|
Tel: 020 7886 2500
(Corporate Finance)
(Corporate Broking)
|
Dowgate Capital Limited (Joint Broker)
David Poutney / James
Serjeant
|
Tel: 020 3903 7715
|
Hudson
Sandler (Financial PR and IR)
Dan de Belder / Hattie Dreyfus
|
Tel: 020 7796 4133
cog@hudsonsandler.com
|
Notes to
Editors
About
Cambridge Cognition
Cambridge Cognition is a technology company
developing digital health products to better understand, detect and
treat conditions affecting brain health. The Company's software
products assess cognitive health in patients worldwide to improve
clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare
industries.
For further information
visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHWPUBGGUPCGQU
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Dec 2023 to Dec 2024